Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.

ABSTRACT:

Background

In the Zurich Primary HIV infection study (ZPHI), minority drug-resistant HIV-1 variants were detected in some acutely HIV-1-infected patients prior to initiation of early antiretroviral therapy (ART). Here, we investigated the reappearance of minority K103N and M184V HIV-1 variants in these patients who interrupted efficient early ART after 8-27 months according to the study protocol. These mutations are key mutations conferring drug resistance to reverse transcriptase inhibitors and they belong to the most commonly transmitted drug resistance mutations.

Methodology/principal findings

Early ART was offered to acutely HIV-1-infected patients enrolled in the longitudinal prospective ZPHI study. Six patients harboring and eleven patients not harboring drug-resistant

SUBMITTER: Metzner KJ 

PROVIDER: S-EPMC3130779 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature